We are live on ! Find out more
SLRN icon

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

109 hedge funds and large institutions have $613M invested in ACELYRIN in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 27 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 27

34% more capital inflows, than outflows

Capital inflows: $148M | Capital outflows: $110M

6.23% more ownership

Funds ownership: 87.12% → 93.35% (+6.2%)

0% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 25

1% less funds holding

Funds holding: 110 → 109 (-1)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

29% less call options, than puts

Call options by funds: $4.79M | Put options by funds: $6.78M

Holders
109
Holders Change
-1
Holders Change %
-0.91%
% of All Funds
1.56%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
25
Increased
45
Reduced
27
Closed
25
Calls
$4.79​M
Puts
$6.78​M
Net Calls
-⁠$1.99​M
Net Calls Change
-⁠$6.43​M

SLRN Hedge Fund Activity: Q1 2024 in Review

109 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q1 2024, worth a combined $613M — down 3.1% from $633M a quarter earlier.

Fund positioning in SLRN was balanced in Q1 2024: 25 funds opened new positions, 25 closed out, 45 added to existing stakes and 27 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $30.5M. The largest seller was Opaleye Management, cutting an estimated $19.5M.

  • 109 institutional investors held ACELYRIN (SLRN) as of Q1 2024, down from 110 in Q4 2023.
  • Funds reported $613M of ACELYRIN stock for Q1 2024, down 3.1% quarter-over-quarter.
  • 25 funds opened new ACELYRIN positions in Q1 2024 and 25 closed out, a net change of 0 holders.
  • The largest ACELYRIN buyer in Q1 2024 was Millennium Management, an estimated $30.5M added.
  • The largest ACELYRIN seller in Q1 2024 was Opaleye Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q1 2024.